Clinical Trial Update: Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of immunoglobulin plus infliximab for Kawasaki Disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kawasaki Disease

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Kawasaki Disease | Phase 3 | Status: WITHDRAWN